REXBURG, ID
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)MOLECULAR EVIDENCE DEVELOPMENT CONSORTIUM, founded in 2015, is a small nonprofit that reported $343K in total revenue in fiscal year 2018. Revenue fell 60% from the prior year — a significant decline worth monitoring. Expenses of $865K exceeded revenue, resulting in a 152% operating deficit.
MED-C WAS A NONPROFIT ORGANIZATION CREATED TO HELP MAKE PERSONALIZED MEDICINE A REALITY. MED-C WAS BRINGING TOGETHER EACH OF HEALTH CARE'S KEY GROUPS - PATIENT, PHYSICIANS, PAYORS, LABS, PHARMA AND REGULATORS TO HELP UNLOCK THE TREMENDOUS POTENTIAL OF PERSONALIZED MEDICINE. TO ACHIEVE THIS GOAL, MED-C HAD LAUNCHED A VAST DATABASE THAT GATHERED GENOMIC-LEVEL DATA ON CANCER PATIENTS AND THOROUGH INFORMATION ABOUT THEIR TREATMENTS AND CLINICAL OUTCOMES.UNFORTUNATELY DUE TO UNFORESEEABLE REGULATORY CIRCUMSTANCES MED-C HAD TO DISCONTINUE IT'S OPERATIONS.
MED-C BEGAN OPERATIONS IN 2015, WITH THE GOAL OF ESTABLISHING INFORMATION TECHNOLOGY INFRASTRUCTURE TO DO CANCER RESEARCH, IRB RESEARCH PROTOCOL, AND INVOLVEMENT IN NATIONAL CANCER PROGRAMS WITH THE...
MED-C BEGAN OPERATIONS IN 2015, WITH THE GOAL OF ESTABLISHING INFORMATION TECHNOLOGY INFRASTRUCTURE TO DO CANCER RESEARCH, IRB RESEARCH PROTOCOL, AND INVOLVEMENT IN NATIONAL CANCER PROGRAMS WITH THE GOAL OF IMPROVING CANCER TREATMENTS AND OUTCOMES FOR CANCER PATIENTS. THE INFORMATION TECHNOLOGY INFRASTRUCTURE WENT OPERATIONAL DURING 2017, HOWEVER DUE TO CHANGES IN GOVERNMENTAL REGULATIONS MED-C WAS UNFORTUNATELY FORCED TO SHUT DOWN IT'S N1 REGISTRY AND DISCOUNTINUE ITS OPERATIONS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2018 | 2017 | Change | |
|---|---|---|---|
| Revenue | $343,299 | $855,663 | -0.6% |
| Expenses | $865,406 | $1,265,873 | -0.3% |
| Net Income | $-522,107 | $-410,210 | +0.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| JEFF ALLEN PHD | Chairman | 3.00 |
Director
|
$0 | $0 | $0 |
| RON COLLETTE CISSP | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MARC SAMUELS JD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| DANE J DICKSON MD | CEO | 40.00 |
Officer
|
$157,154 | $0 | $157,154 |
| REBECCA OWENS | COO | 40.00 |
Officer
|
$117,181 | $0 | $117,181 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2018 | $343,299 | $865,406 | No data | $-522,107 |
Compare MOLECULAR EVIDENCE DEVELOPMENT CONSORTIUM with other nonprofits in Idaho and across the country.